Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
Marks significant milestone for breakthrough biologic to treat rare blood cancers
The pioneering monoclonal antibody is for Essential Thrombocythemia (ET) and Polycythemia Vera (PV), rare chronic blood cancers with limited treatment options
The initiation of a second Phase 3 clinical trial for bomedemstat demonstrates company’s commitment to advancing research in myeloproliferative neoplasms (MPNs)
Approval is for use in myelofibrosis patients with anaemia regardless of prior myelofibrosis therapy
Acquisition expands Merck’s growing hematology portfolio
Subscribe To Our Newsletter & Stay Updated
